bomedemstat

Bomedemstat (IMG-7289) is an orally active, irreversible inhibitor of lysine-specific demethylase 1 (LSD1) that exhibits antineoplastic activities in mouse models of myeloproliferative neoplasms (MPNs), and can be used for research on acute myelogenous leukemia (AML) and myelofibrosis (MF) [1].

Bomedemstat ditosylate (IMG-7289 ditosylate) is an orally active lysine-specific demethylase 1 (LSD1) inhibitor with antitumor activity that potentiates the response to PD-1 inhibition in a homozygous model of SCLC, inhibits cancer cell proliferation, and induces apoptosis. Bomedemstat ditosylate can be used to study myeloproliferative neoplasms and myelofibrosis.

Bomedemstat (IMG-7289) hydrochloride is an orally active, irreversible inhibitor of lysine-specific demethylase 1 (LSD1), exhibiting anticancer effects by inhibiting cancer cell proliferation and inducing apoptosis.

CT-179 is a potent and selective inhibitor of oligodendrocyte transcription factor 2 (OLIG2), reduces tumor cell proliferation and induces apoptosis, and enhances efficacy when used in combination with radiotherapy and other agents, showing potential in the treatment of medulloblastoma and glioblastoma.